Altimmune Inc (ALT) concluded trading on Wednesday at a closing price of $6.78, with 5.71 million shares of worth about $38.71 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.92% during that period and on June 18, 2025 the price saw a loss of about -1.60%. Currently the company’s common shares owned by public are about 81.11M shares, out of which, 80.26M shares are available for trading.
Stock saw a price change of 3.67% in past 5 days and over the past one month there was a price change of 23.27%. Year-to-date (YTD), ALT shares are showing a performance of -5.96% which increased to 10.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.55 but also hit the highest price of $11.16 during that period. The average intraday trading volume for Altimmune Inc shares is 2.57 million. The stock is currently trading 12.77% above its 20-day simple moving average (SMA20), while that difference is up 23.99% for SMA50 and it goes to 3.44% higher than SMA200.
Altimmune Inc (NASDAQ: ALT) currently have 81.11M outstanding shares and institutions hold larger chunk of about 47.38% of that.
The stock has a current market capitalization of $549.91M and its 3Y-monthly beta is at 0.57. It has posted earnings per share of -$1.25 in the same period. It has Quick Ratio of 15.82 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALT, volatility over the week remained 1.51% while standing at 4.36% over the month.
Stock’s fiscal year EPS is expected to rise by 5.73% while it is estimated to decrease by -7.13% in next year. EPS is likely to shrink at an annualized rate of 0.60% for next 5-years, compared to annual growth of 3.48% made by the stock over the past 5-years.
Coverage by Stifel stated Altimmune Inc (ALT) stock as a Buy in their note to investors on January 08, 2025, suggesting a price target of $18 for the stock. Stock get a Neutral rating from Goldman on January 24, 2024.
